Proactive One2One Investor Forum

In brief · summary, not quotable

Coiled Therapeutics plc announced its participation in the Proactive One2One Investor Forum in London on June 24, 2026, where Chairman Sotirios Stergiopoulos will present. The company, listed on AIM and OTCQB, is developing precision medicines for hard-to-treat cancers, with its lead program AO-252, a TACC3 inhibitor, currently in Phase I clinical trials in the USA. The presentation will be available on the company's website, and investors can register for the event online.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that it will be presenting at the Proactive One2One Investor Forum (the "Forum") in London on Wednesday 24 June 2026 at 6.00 pm.

The Forum will be hosted at The Chesterfield Mayfair, 35 Charles Street, London, W1J 5EB.

Coiled Therapeutics' Chairman Sotirios Stergiopoulos will be delivering a presentation, which will be made available on the Company's website: www.coiledplc.com

In order to register for the event, please use the following link:

About AO-252

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, a key differentiator that may enable treatment of both primary brain tumours and brain metastases, areas of significant unmet medical need. Preclinical and early clinical observations support further evaluation of the programme's potential across multiple tumour types.

AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study in the United States. Early clinical observations have demonstrated encouraging anti-tumour activity and a favourable safety profile, with the Company planning to initiate dose expansion cohorts in selected indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com and follow us on LinkedIn.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.